ID   FINC_MOUSE              Reviewed;        2477 AA.
AC   P11276; G5E8B8; Q61567; Q61568; Q61569; Q64233; Q80UI4;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2012, sequence version 4.
DT   07-APR-2021, entry version 220.
DE   RecName: Full=Fibronectin {ECO:0000305};
DE            Short=FN;
DE   Contains:
DE     RecName: Full=Anastellin;
DE   Flags: Precursor;
GN   Name=Fn1 {ECO:0000312|MGI:MGI:95566};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S., She X.,
RA   Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W., Kapustin Y.,
RA   Meric P., Maglott D., Birtle Z., Marques A.C., Graves T., Zhou S.,
RA   Teague B., Potamousis K., Churas C., Place M., Herschleb J., Runnheim R.,
RA   Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z., Lindblad-Toh K.,
RA   Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of the
RT   mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-920.
RC   STRAIN=FVB/N-3; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-28.
RC   TISSUE=Liver;
RX   PubMed=8299972; DOI=10.1016/0378-1119(93)90036-3;
RA   Polly P., Nicholson R.C.;
RT   "Sequence of the mouse fibronectin-encoding gene promoter region.";
RL   Gene 137:353-354(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 562-834.
RC   STRAIN=NMRI;
RX   PubMed=7673336;
RA   Talts J.F., Weller A., Timpl R., Ekblom M., Ekblom P.;
RT   "Regulation of mesenchymal extracellular matrix protein synthesis by
RT   transforming growth factor-beta and glucocorticoids in tumor stroma.";
RL   J. Cell Sci. 108:2153-2162(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 899-2376.
RA   Gorski G., Aros M., Norton P.;
RL   Submitted (DEC-1995) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2375-2477.
RX   PubMed=3124113; DOI=10.1073/pnas.85.4.1119;
RA   Blatti S.P., Foster D.N., Ranganthan G., Moses H.L., Getz M.J.;
RT   "Induction of fibronectin gene transcription and mRNA is a primary response
RT   to growth-factor stimulation of AKR-2B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1119-1123(1988).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2375-2477.
RX   PubMed=2521606; DOI=10.1016/0014-4827(89)90080-3;
RA   Ryseck R.P., MacDonald-Bravo H., Zerial M., Bravo R.;
RT   "Coordinate induction of fibronectin, fibronectin receptor, tropomyosin,
RT   and actin genes in serum-stimulated fibroblasts.";
RL   Exp. Cell Res. 180:537-545(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2375-2477.
RC   TISSUE=Kidney;
RX   PubMed=1327855; DOI=10.1016/0014-4827(92)90100-m;
RA   Khandjian E.W., Salomon C., Leonard N., Tremblay S., Turler H.;
RT   "Fibronectin gene expression in proliferating, quiescent, and SV40-infected
RT   mouse kidney cells.";
RL   Exp. Cell Res. 202:464-470(1992).
RN   [10]
RP   TRANSGLUTAMINATION AT GLN-35; GLN-36 AND GLN-48, AND MUTAGENESIS OF GLN-35;
RP   GLN-36 AND GLN-48.
RX   PubMed=9312106; DOI=10.1074/jbc.272.40.24999;
RA   Corbett S.A., Lee L., Wilson C.L., Schwarzbauer J.E.;
RT   "Covalent cross-linking of fibronectin to fibrin is required for maximal
RT   cell adhesion to a fibronectin-fibrin matrix.";
RL   J. Biol. Chem. 272:24999-25005(1997).
RN   [11]
RP   DOWN-REGULATION BY GLUCOCORTICOIDS.
RX   PubMed=11737251; DOI=10.1034/j.1600-0609.2001.5790528.x;
RA   Gu Y.-C., Talts J.F., Gullberg D., Timpl R., Ekblom M.;
RT   "Glucocorticoids down-regulate the extracellular matrix proteins
RT   fibronectin, fibulin-1 and fibulin-2 in bone marrow stroma.";
RL   Eur. J. Haematol. 67:176-184(2001).
RN   [12]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1006.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=16944957; DOI=10.1021/pr060186m;
RA   Ghesquiere B., Van Damme J., Martens L., Vandekerckhove J., Gevaert K.;
RT   "Proteome-wide characterization of N-glycosylation events by diagonal
RT   chromatography.";
RL   J. Proteome Res. 5:2438-2447(2006).
RN   [13]
RP   INTERACTION WITH FBLN7.
RX   PubMed=17699513; DOI=10.1074/jbc.m705847200;
RA   de Vega S., Iwamoto T., Nakamura T., Hozumi K., McKnight D.A., Fisher L.W.,
RA   Fukumoto S., Yamada Y.;
RT   "TM14 is a new member of the fibulin family (fibulin-7) that interacts with
RT   extracellular matrix molecules and is active for cell binding.";
RL   J. Biol. Chem. 282:30878-30888(2007).
RN   [14]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528.
RC   STRAIN=C57BL/6J; TISSUE=Plasma;
RX   PubMed=17330941; DOI=10.1021/pr0604559;
RA   Bernhard O.K., Kapp E.A., Simpson R.J.;
RT   "Enhanced analysis of the mouse plasma proteome using cysteine-containing
RT   tryptic glycopeptides.";
RL   J. Proteome Res. 6:987-995(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2475, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2475, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18630941; DOI=10.1021/pr800223m;
RA   Zhou H., Ye M., Dong J., Han G., Jiang X., Wu R., Zou H.;
RT   "Specific phosphopeptide enrichment with immobilized titanium ion affinity
RT   chromatography adsorbent for phosphoproteome analysis.";
RL   J. Proteome Res. 7:3957-3967(2008).
RN   [17]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-528; ASN-1006; ASN-1290 AND
RP   ASN-2198.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.m900195-mcp200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I., Bausch-Fluck D.,
RA   Elliott S.T., Boheler K.R., Van Eyk J.E., Wollscheid B.;
RT   "The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation.";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2475, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic fibroblast;
RX   PubMed=19131326; DOI=10.1074/mcp.m800451-mcp200;
RA   Sweet S.M., Bailey C.M., Cunningham D.L., Heath J.K., Cooper H.J.;
RT   "Large scale localization of protein phosphorylation by use of electron
RT   capture dissociation mass spectrometry.";
RL   Mol. Cell. Proteomics 8:904-912(2009).
RN   [19]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1006 AND ASN-1290.
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-285 AND SER-2475, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung, Pancreas,
RC   Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [21]
RP   FUNCTION.
RX   PubMed=21768292; DOI=10.1083/jcb.201007108;
RA   Brunner M., Millon-Fremillon A., Chevalier G., Nakchbandi I.A., Mosher D.,
RA   Block M.R., Albiges-Rizo C., Bouvard D.;
RT   "Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent
RT   fibronectin deposition.";
RL   J. Cell Biol. 194:307-322(2011).
RN   [22]
RP   OXIDATION.
RX   PubMed=26954549; DOI=10.1016/j.devcel.2016.02.009;
RA   Kraft-Sheleg O., Zaffryar-Eilot S., Genin O., Yaseen W.,
RA   Soueid-Baumgarten S., Kessler O., Smolkin T., Akiri G., Neufeld G.,
RA   Cinnamon Y., Hasson P.;
RT   "Localized LoxL3-dependent fibronectin oxidation regulates myofiber stretch
RT   and integrin-mediated adhesion.";
RL   Dev. Cell 36:550-561(2016).
RN   [23]
RP   TISSUE SPECIFICITY.
RX   PubMed=29777959; DOI=10.1016/j.actbio.2018.05.023;
RA   Felemban M., Dorgau B., Hunt N.C., Hallam D., Zerti D., Bauer R., Ding Y.,
RA   Collin J., Steel D., Krasnogor N., Al-Aama J., Lindsay S., Mellough C.,
RA   Lako M.;
RT   "Extracellular matrix component expression in human pluripotent stem cell-
RT   derived retinal organoids recapitulates retinogenesis in vivo and reveals
RT   an important role for IMPG1 and CD44 in the development of photoreceptors
RT   and interphotoreceptor matrix.";
RL   Acta Biomater. 74:207-221(2018).
RN   [24]
RP   STRUCTURE BY NMR OF 1447-1630.
RX   PubMed=9533887; DOI=10.1006/jmbi.1998.1616;
RA   Copie V., Tomita Y., Akiyama S.K., Aota S., Yamada K.M., Venable R.M.,
RA   Pastor R.W., Krueger S., Torchia D.A.;
RT   "Solution structure and dynamics of linked cell attachment modules of mouse
RT   fibronectin containing the RGD and synergy regions: comparison with the
RT   human fibronectin crystal structure.";
RL   J. Mol. Biol. 277:663-682(1998).
CC   -!- FUNCTION: Fibronectins bind cell surfaces and various compounds
CC       including collagen, fibrin, heparin, DNA, and actin (By similarity).
CC       Fibronectins are involved in cell adhesion, cell motility,
CC       opsonization, wound healing, and maintenance of cell shape healing, and
CC       maintenance of cell shape (By similarity). Involved in osteoblast
CC       compaction through the fibronectin fibrillogenesis cell-mediated matrix
CC       assembly process, essential for osteoblast mineralization
CC       (PubMed:21768292). Participates in the regulation of type I collagen
CC       deposition by osteoblasts (PubMed:21768292).
CC       {ECO:0000250|UniProtKB:P02751, ECO:0000269|PubMed:21768292}.
CC   -!- FUNCTION: [Anastellin]: Binds fibronectin and induces fibril formation.
CC       This fibronectin polymer, named superfibronectin, exhibits enhanced
CC       adhesive properties. Both anastellin and superfibronectin inhibit tumor
CC       growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and
CC       inhibits lysophospholipid signaling. {ECO:0000250|UniProtKB:P02751}.
CC   -!- SUBUNIT: Mostly heterodimers or multimers of alternatively spliced
CC       variants, connected by 2 disulfide bonds near the carboxyl ends; to a
CC       lesser extent homodimers. Interacts with FBLN1, AMBP, LGALS3BP and
CC       COL13A1 and COMP (By similarity). Interacts with TNR; interaction
CC       mediates inhibition of cell adhesion and neurite outgrowth. Interacts
CC       with FBLN7. Interacts with FST3 and MYOC (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P11276; Q8CIH5: Plcg2; NbExp=6; IntAct=EBI-641955, EBI-617954;
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=1;
CC         Comment=A number of isoforms are produced. The diversity of isoforms
CC         depends on the V region and either of the two extra domain which can
CC         be either included or excluded (partially or completely for the V
CC         region). {ECO:0000305};
CC       Name=1;
CC         IsoId=P11276-1; Sequence=Displayed;
CC   -!- TISSUE SPECIFICITY: Expressed in the inner limiting membrane and around
CC       blood vessels in the retina (at protein level) (PubMed:29777959).
CC       Plasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular
CC       FN (dimeric or cross-linked multimeric forms), made by fibroblasts,
CC       epithelial and other cell types, is deposited as fibrils in the
CC       extracellular matrix. {ECO:0000269|PubMed:29777959}.
CC   -!- INDUCTION: Glucocorticoids suppressed mRNA expression and protein
CC       synthesis.
CC   -!- PTM: Sulfated. {ECO:0000250|UniProtKB:P02751}.
CC   -!- PTM: Forms covalent cross-links mediated by a transglutaminase, such as
CC       F13A or TGM2, between a glutamine and the epsilon-amino group of a
CC       lysine residue, forming homopolymers and heteropolymers (e.g.
CC       fibrinogen-fibronectin, collagen-fibronectin heteropolymers).
CC       {ECO:0000269|PubMed:9312106}.
CC   -!- PTM: Phosphorylated by FAM20C in the extracellular medium.
CC       {ECO:0000250|UniProtKB:P02751}.
CC   -!- PTM: Proteolytic processing produces the C-terminal NC1 peptide,
CC       anastellin. {ECO:0000250|UniProtKB:P02751}.
CC   -!- PTM: Some lysine residues are oxidized to allysine by LOXL3, promoting
CC       fibronectin activation and matrix formation.
CC       {ECO:0000269|PubMed:26954549}.
CC   -!- PTM: Serotonylated on Gln residues by TGM2 in response to hypoxia.
CC       {ECO:0000250|UniProtKB:P07589}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AC124821; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH466548; EDL00265.1; -; Genomic_DNA.
DR   EMBL; BC051082; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Z22729; CAA80422.1; -; Genomic_DNA.
DR   EMBL; X82402; CAA57796.1; -; mRNA.
DR   EMBL; X93167; CAA63654.1; -; mRNA.
DR   EMBL; M18194; AAA37636.1; -; mRNA.
DR   EMBL; S45680; AAB23491.1; -; mRNA.
DR   CCDS; CCDS15031.1; -. [P11276-1]
DR   PIR; A49173; A49173.
DR   PIR; I48349; I48349.
DR   RefSeq; NP_034363.1; NM_010233.2. [P11276-1]
DR   PDB; 1MFN; NMR; -; A=1447-1630.
DR   PDB; 2MFN; NMR; -; A=1447-1630.
DR   PDBsum; 1MFN; -.
DR   PDBsum; 2MFN; -.
DR   SMR; P11276; -.
DR   BioGRID; 199719; 24.
DR   CORUM; P11276; -.
DR   ELM; P11276; -.
DR   IntAct; P11276; 7.
DR   MINT; P11276; -.
DR   STRING; 10090.ENSMUSP00000054499; -.
DR   GlyGen; P11276; 8 sites.
DR   iPTMnet; P11276; -.
DR   PhosphoSitePlus; P11276; -.
DR   SwissPalm; P11276; -.
DR   CPTAC; non-CPTAC-3296; -.
DR   CPTAC; non-CPTAC-3538; -.
DR   EPD; P11276; -.
DR   jPOST; P11276; -.
DR   MaxQB; P11276; -.
DR   PaxDb; P11276; -.
DR   PeptideAtlas; P11276; -.
DR   PRIDE; P11276; -.
DR   ProteomicsDB; 271764; -. [P11276-1]
DR   ABCD; P11276; 8 sequenced antibodies.
DR   Antibodypedia; 3522; 2657 antibodies.
DR   Ensembl; ENSMUST00000055226; ENSMUSP00000054499; ENSMUSG00000026193. [P11276-1]
DR   GeneID; 14268; -.
DR   KEGG; mmu:14268; -.
DR   UCSC; uc007bju.2; mouse. [P11276-1]
DR   CTD; 2335; -.
DR   MGI; MGI:95566; Fn1.
DR   eggNOG; ENOG502QPTS; Eukaryota.
DR   GeneTree; ENSGT00940000155126; -.
DR   InParanoid; P11276; -.
DR   TreeFam; TF329915; -.
DR   Reactome; R-MMU-114608; Platelet degranulation.
DR   Reactome; R-MMU-1474228; Degradation of the extracellular matrix.
DR   Reactome; R-MMU-1474244; Extracellular matrix organization.
DR   Reactome; R-MMU-1566977; Fibronectin matrix formation.
DR   Reactome; R-MMU-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-MMU-2129379; Molecules associated with elastic fibres.
DR   Reactome; R-MMU-216083; Integrin cell surface interactions.
DR   Reactome; R-MMU-3000170; Syndecan interactions.
DR   Reactome; R-MMU-3000171; Non-integrin membrane-ECM interactions.
DR   Reactome; R-MMU-3000178; ECM proteoglycans.
DR   Reactome; R-MMU-354192; Integrin signaling.
DR   Reactome; R-MMU-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-MMU-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-MMU-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-MMU-5674135; MAP2K and MAPK activation.
DR   Reactome; R-MMU-8874081; MET activates PTK2 signaling.
DR   Reactome; R-MMU-8957275; Post-translational protein phosphorylation.
DR   BioGRID-ORCS; 14268; 1 hit in 52 CRISPR screens.
DR   ChiTaRS; Fn1; mouse.
DR   EvolutionaryTrace; P11276; -.
DR   PRO; PR:P11276; -.
DR   Proteomes; UP000000589; Chromosome 1.
DR   RNAct; P11276; protein.
DR   Bgee; ENSMUSG00000026193; Expressed in vault of skull and 327 other tissues.
DR   Genevisible; P11276; MM.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:MGI.
DR   GO; GO:0005604; C:basement membrane; IDA:MGI.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:UniProtKB.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; ISO:MGI.
DR   GO; GO:0070062; C:extracellular exosome; ISO:MGI.
DR   GO; GO:0031012; C:extracellular matrix; IDA:MGI.
DR   GO; GO:0005615; C:extracellular space; HDA:BHF-UCL.
DR   GO; GO:0005577; C:fibrinogen complex; ISO:MGI.
DR   GO; GO:0051087; F:chaperone binding; ISO:MGI.
DR   GO; GO:0097718; F:disordered domain specific binding; ISO:MGI.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0005178; F:integrin binding; ISO:MGI.
DR   GO; GO:0045340; F:mercury ion binding; ISO:MGI.
DR   GO; GO:0016504; F:peptidase activator activity; IDA:MGI.
DR   GO; GO:0002020; F:protease binding; ISO:MGI.
DR   GO; GO:0008022; F:protein C-terminus binding; ISO:MGI.
DR   GO; GO:0043394; F:proteoglycan binding; ISO:MGI.
DR   GO; GO:0005102; F:signaling receptor binding; ISO:MGI.
DR   GO; GO:0006953; P:acute-phase response; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0051702; P:biological process involved in interaction with symbiont; ISO:MGI.
DR   GO; GO:0072378; P:blood coagulation, fibrin clot formation; IBA:GO_Central.
DR   GO; GO:0007161; P:calcium-independent cell-matrix adhesion; IDA:MGI.
DR   GO; GO:0001775; P:cell activation; ISO:MGI.
DR   GO; GO:0007155; P:cell adhesion; IDA:MGI.
DR   GO; GO:0007160; P:cell-matrix adhesion; IDA:MGI.
DR   GO; GO:0007044; P:cell-substrate junction assembly; IDA:MGI.
DR   GO; GO:0071347; P:cellular response to interleukin-1; ISO:MGI.
DR   GO; GO:0071288; P:cellular response to mercury ion; ISO:MGI.
DR   GO; GO:0035987; P:endodermal cell differentiation; ISO:MGI.
DR   GO; GO:0030198; P:extracellular matrix organization; ISO:MGI.
DR   GO; GO:0008347; P:glial cell migration; ISO:MGI.
DR   GO; GO:0007507; P:heart development; IBA:GO_Central.
DR   GO; GO:0033622; P:integrin activation; ISO:MGI.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; ISO:MGI.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISO:MGI.
DR   GO; GO:0032966; P:negative regulation of collagen biosynthetic process; ISO:MGI.
DR   GO; GO:0071635; P:negative regulation of transforming growth factor beta production; ISO:MGI.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:1901166; P:neural crest cell migration involved in autonomic nervous system development; ISO:MGI.
DR   GO; GO:0018149; P:peptide cross-linking; ISO:MGI.
DR   GO; GO:0070527; P:platelet aggregation; IBA:GO_Central.
DR   GO; GO:0045773; P:positive regulation of axon extension; IDA:MGI.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISO:MGI.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISO:MGI.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISO:MGI.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; ISO:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISO:MGI.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISO:MGI.
DR   GO; GO:1904237; P:positive regulation of substrate-dependent cell migration, cell attachment to substrate; ISO:MGI.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:UniProtKB-KW.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; ISO:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:MGI.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; ISO:MGI.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; ISO:MGI.
DR   GO; GO:0042060; P:wound healing; IMP:MGI.
DR   CDD; cd00061; FN1; 12.
DR   CDD; cd00062; FN2; 2.
DR   CDD; cd00063; FN3; 17.
DR   Gene3D; 2.10.10.10; -; 2.
DR   Gene3D; 2.60.40.10; -; 17.
DR   InterPro; IPR000083; Fibronectin_type1.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR000562; FN_type2_dom.
DR   InterPro; IPR036943; FN_type2_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013806; Kringle-like.
DR   Pfam; PF00039; fn1; 11.
DR   Pfam; PF00040; fn2; 2.
DR   Pfam; PF00041; fn3; 17.
DR   SMART; SM00058; FN1; 12.
DR   SMART; SM00059; FN2; 2.
DR   SMART; SM00060; FN3; 17.
DR   SUPFAM; SSF49265; SSF49265; 11.
DR   SUPFAM; SSF57440; SSF57440; 2.
DR   PROSITE; PS00022; EGF_1; 2.
DR   PROSITE; PS01253; FN1_1; 12.
DR   PROSITE; PS51091; FN1_2; 12.
DR   PROSITE; PS00023; FN2_1; 2.
DR   PROSITE; PS51092; FN2_2; 2.
DR   PROSITE; PS50853; FN3; 17.
PE   1: Evidence at protein level;
KW   3D-structure; Acute phase; Alternative splicing; Angiogenesis;
KW   Cell adhesion; Cell shape; Disulfide bond; Extracellular matrix;
KW   Glycoprotein; Heparin-binding; Isopeptide bond; Oxidation; Phosphoprotein;
KW   Pyrrolidone carboxylic acid; Reference proteome; Repeat; Secreted; Signal;
KW   Sulfation.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000250|UniProtKB:P02751"
FT   CHAIN           33..2477
FT                   /note="Fibronectin"
FT                   /id="PRO_0000019236"
FT   CHAIN           627..701
FT                   /note="Anastellin"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000390480"
FT   DOMAIN          51..91
FT                   /note="Fibronectin type-I 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          96..139
FT                   /note="Fibronectin type-I 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          140..183
FT                   /note="Fibronectin type-I 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          185..229
FT                   /note="Fibronectin type-I 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          230..274
FT                   /note="Fibronectin type-I 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          306..343
FT                   /note="Fibronectin type-I 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          355..403
FT                   /note="Fibronectin type-II 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478,
FT                   ECO:0000255|PROSITE-ProRule:PRU00479"
FT   DOMAIN          415..463
FT                   /note="Fibronectin type-II 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478,
FT                   ECO:0000255|PROSITE-ProRule:PRU00479"
FT   DOMAIN          468..516
FT                   /note="Fibronectin type-I 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          516..558
FT                   /note="Fibronectin type-I 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          559..602
FT                   /note="Fibronectin type-I 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          610..717
FT                   /note="Fibronectin type-III 1"
FT   DOMAIN          721..811
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          812..903
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          908..997
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          998..1087
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1088..1174
FT                   /note="Fibronectin type-III 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1175..1269
FT                   /note="Fibronectin type-III 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1270..1358
FT                   /note="Fibronectin type-III 8; extra domain B"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1359..1451
FT                   /note="Fibronectin type-III 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1452..1539
FT                   /note="Fibronectin type-III 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1540..1633
FT                   /note="Fibronectin type-III 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1634..1725
FT                   /note="Fibronectin type-III 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1726..1813
FT                   /note="Fibronectin type-III 13; extra domain A"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316,
FT                   ECO:0000255|PROSITE-ProRule:PRU00478, ECO:0000255|PROSITE-
FT                   ProRule:PRU00479"
FT   DOMAIN          1814..1907
FT                   /note="Fibronectin type-III 14"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1908..1994
FT                   /note="Fibronectin type-III 15"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1995..2085
FT                   /note="Fibronectin type-III 16"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2193..2287
FT                   /note="Fibronectin type-III 17"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          2294..2338
FT                   /note="Fibronectin type-I 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          2339..2381
FT                   /note="Fibronectin type-I 11"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DOMAIN          2383..2426
FT                   /note="Fibronectin type-I 12"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00478"
FT   DNA_BIND        906..1171
FT   REGION          53..273
FT                   /note="Fibrin- and heparin-binding 1"
FT   REGION          308..608
FT                   /note="Collagen-binding"
FT   REGION          1357..1630
FT                   /note="Cell-attachment"
FT   REGION          1811..2081
FT                   /note="Heparin-binding 2"
FT   REGION          2082..2201
FT                   /note="V region (type III connecting segment, IIICS)"
FT   REGION          2296..2427
FT                   /note="Fibrin-binding 2"
FT   MOTIF           1614..1616
FT                   /note="Cell attachment site"
FT   MOTIF           2181..2183
FT                   /note="Cell attachment site"
FT   MOD_RES         33
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000250|UniProtKB:P02751"
FT   MOD_RES         285
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         875
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         880
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         2392
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         2454
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P02751"
FT   MOD_RES         2475
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17242355,
FT                   ECO:0007744|PubMed:18630941, ECO:0007744|PubMed:19131326,
FT                   ECO:0007744|PubMed:21183079"
FT   CARBOHYD        430
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        528
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17330941,
FT                   ECO:0000269|PubMed:19656770"
FT   CARBOHYD        542
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        876
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1006
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16944957,
FT                   ECO:0000269|PubMed:19349973, ECO:0000269|PubMed:19656770"
FT   CARBOHYD        1243
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1290
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973,
FT                   ECO:0000269|PubMed:19656770"
FT   CARBOHYD        2198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19656770"
FT   DISULFID        53..79
FT                   /evidence="ECO:0000250"
FT   DISULFID        77..88
FT                   /evidence="ECO:0000250"
FT   DISULFID        98..126
FT                   /evidence="ECO:0000250"
FT   DISULFID        124..136
FT                   /evidence="ECO:0000250"
FT   DISULFID        142..170
FT                   /evidence="ECO:0000250"
FT   DISULFID        168..180
FT                   /evidence="ECO:0000250"
FT   DISULFID        187..216
FT                   /evidence="ECO:0000250"
FT   DISULFID        214..226
FT                   /evidence="ECO:0000250"
FT   DISULFID        232..261
FT                   /evidence="ECO:0000250"
FT   DISULFID        259..271
FT                   /evidence="ECO:0000250"
FT   DISULFID        308..335
FT                   /evidence="ECO:0000250"
FT   DISULFID        333..342
FT                   /evidence="ECO:0000250"
FT   DISULFID        360..386
FT                   /evidence="ECO:0000250"
FT   DISULFID        374..401
FT                   /evidence="ECO:0000250"
FT   DISULFID        420..446
FT                   /evidence="ECO:0000250"
FT   DISULFID        434..461
FT                   /evidence="ECO:0000250"
FT   DISULFID        470..498
FT                   /evidence="ECO:0000250"
FT   DISULFID        496..508
FT                   /evidence="ECO:0000250"
FT   DISULFID        518..545
FT                   /evidence="ECO:0000250"
FT   DISULFID        543..555
FT                   /evidence="ECO:0000250"
FT   DISULFID        561..589
FT                   /evidence="ECO:0000250"
FT   DISULFID        587..599
FT                   /evidence="ECO:0000250"
FT   DISULFID        2296..2325
FT                   /evidence="ECO:0000250"
FT   DISULFID        2323..2335
FT                   /evidence="ECO:0000250"
FT   DISULFID        2341..2368
FT                   /evidence="ECO:0000250"
FT   DISULFID        2366..2378
FT                   /evidence="ECO:0000250"
FT   DISULFID        2385..2411
FT                   /evidence="ECO:0000250"
FT   DISULFID        2409..2420
FT                   /evidence="ECO:0000250"
FT   DISULFID        2458
FT                   /note="Interchain (with C-2462)"
FT   DISULFID        2462
FT                   /note="Interchain (with C-2458)"
FT   CROSSLNK        35
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   CROSSLNK        36
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   CROSSLNK        48
FT                   /note="Isoglutamyl lysine isopeptide (Gln-Lys) (interchain
FT                   with K-?)"
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   MUTAGEN         35
FT                   /note="Q->A: 99% decrease in cross-linking efficiency; when
FT                   associated with A-36 and A-48."
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   MUTAGEN         35
FT                   /note="Q->L: 65% decrease in cross-linking efficiency; when
FT                   associated with L-36."
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   MUTAGEN         36
FT                   /note="Q->A: 99% decrease in cross-linking efficiency; when
FT                   associated with A-35 and A-48."
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   MUTAGEN         36
FT                   /note="Q->L: 65% decrease in cross-linking efficiency; when
FT                   associated with L-35."
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   MUTAGEN         48
FT                   /note="Q->A: 99% decrease in cross-linking efficiency; when
FT                   associated with A-35 and A-36."
FT                   /evidence="ECO:0000269|PubMed:9312106"
FT   CONFLICT        1063
FT                   /note="V -> A (in Ref. 6; CAA63654)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1820
FT                   /note="F -> L (in Ref. 6; CAA63654)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2440
FT                   /note="T -> N (in Ref. 7; AAA37636)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1455..1459
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1461..1467
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1476..1484
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1492..1496
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1501..1507
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1510..1521
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1530..1536
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1545..1550
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1553..1557
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1567..1580
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1582..1586
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1591..1594
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1600..1612
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1615..1617
FT                   /evidence="ECO:0007744|PDB:1MFN"
FT   STRAND          1624..1630
FT                   /evidence="ECO:0007744|PDB:1MFN"
SQ   SEQUENCE   2477 AA;  272538 MW;  24A207BE67F85585 CRC64;
     MLRGPGPGRL LLLAVLCLGT SVRCTEAGKS KRQAQQIVQP QSPVAVSQSK PGCFDNGKHY
     QINQQWERTY LGNALVCTCY GGSRGFNCES KPEPEETCFD KYTGNTYKVG DTYERPKDSM
     IWDCTCIGAG RGRISCTIAN RCHEGGQSYK IGDKWRRPHE TGGYMLECLC LGNGKGEWTC
     KPIAEKCFDH AAGTSYVVGE TWEKPYQGWM MVDCTCLGEG NGRITCTSRN RCNDQDTRTS
     YRIGDTWSKK DNRGNLLQCV CTGNGRGEWK CERHALQSAS AGSGSFTDVR TAIYQPQTHP
     QPAPYGHCVT DSGVVYSVGM QWLKSQGNKQ MLCTCLGNGV SCQETAVTQT YGGNSNGEPC
     VLPFTYNGRT FYSCTTEGRQ DGHLWCSTTS NYEQDQKYSF CTDHAVLVQT RGGNSNGALC
     HFPFLYNNRN YTDCTSEGRR DNMKWCGTTQ NYDADQKFGF CPMAAHEEIC TTNEGVMYRI
     GDQWDKQHDL GHMMRCTCVG NGRGEWACIP YSQLRDQCIV DDITYNVNDT FHKRHEEGHM
     LNCTCFGQGR GRWKCDPIDQ CQDSETRTFY QIGDSWEKFV HGVRYQCYCY GRGIGEWHCQ
     PLQTYPGTTG PVQVIITETP SQPNSHPIQW NAPEPSHITK YILRWRPKTS TGRWKEATIP
     GHLNSYTIKG LTPGVIYEGQ LISIQQYGHR EVTRFDFTTS ASTPVTSNTV TGETAPYSPV
     VATSESVTEI TASSFVVSWV SASDTVSGFR VEYELSEEGD EPQYLDLPST ATSVNIPDLL
     PGRKYIVNVY QISEEGKQSL ILSTSQTTAP DAPPDPTVDQ VDDTSIVVRW SRPQAPITGY
     RIVYSPSVEG SSTELNLPET ANSVTLSDLQ PGVQYNITIY AVEENQESTP VFIQQETTGT
     PRSDNVPPPT DLQFVELTDV KVTIMWTPPD SVVSGYRVEV LPVSLPGEHG QRLPVNRNTF
     AEITGLSPGV TYLFKVFAVH QGRESNPLTA QQTTKLDAPT NLQFVNETDR TVLVTWTPPR
     ARIAGYRLTA GLTRGGQPKQ YNVGPLASKY PLRNLQPGSE YTVTLVAVKG NQQSPKATGV
     FTTLQPLRSI PPYNTEVTET TIVITWTPAP RIGFKLGVRP SQGGEAPREV TSDSGSIVVS
     GLTPGVEYTY TIQVLRDGQE RDAPIVNRVV TPLSPPTNLH LEANPDTGVL TVSWERSTTP
     DITGYRITTT PTNGQQGTSL EEVVHADQSS CTFENLNPGL EYNVSVYTVK DDKESAPISD
     TVVPEVPQLT DLSFVDITDS SIGLRWTPLN SSTIIGYRIT VVAAGEGIPI FEDFVDSSVG
     YYTVTGLEPG IDYDISVITL INGGESAPTT LTQQTAVPPP TDLRFTNIGP DTMRVTWAPP
     PSIELTNLLV RYSPVKNEED VAELSISPSD NAVVLTNLLP GTEYLVSVSS VYEQHESIPL
     RGRQKTGLDS PTGFDSSDIT ANSFTVHWVA PRAPITGYII RHHAEHSVGR PRQDRVPPSR
     NSITLTNLNP GTEYVVSIIA VNGREESPPL IGQQATVSDI PRDLEVIAST PTSLLISWEP
     PAVSVRYYRI TYGETGGNSP VQEFTVPGSK STATINNIKP GADYTITLYA VTGRGDSPAS
     SKPVSINYKT EIDKPSQMQV TDVQDNSISV RWLPSTSPVT GYRVTTTPKN GLGPSKTKTA
     SPDQTEMTIE GLQPTVEYVV SVYAQNRNGE SQPLVQTAVT NIDRPKGLAF TDVDVDSIKI
     AWESPQGQVS RYRVTYSSPE DGIRELFPAP DGEDDTAELQ GLRPGSEYTV SVVALHDDME
     SQPLIGIQST AIPAPTNLKF SQVTPTSFTA QWIAPSVQLT GYRVRVNPKE KTGPMKEINL
     SPDSSSVIVS GLMVATKYEV SVYALKDTLT SRPAQGVITT LENVSPPRRA RVTDATETTI
     TISWRTKTET ITGFQVDAIP ANGQTPVQRS ISPDVRSYTI TGLQPGTDYK IHLYTLNDNA
     RSSPVIIDAS TAIDAPSNLR FLTTTPNSLL VSWQAPRARI TGYIIKYEKP GSPPREVVPR
     PRPGVTEATI TGLEPGTEYT IYVIALKNNQ KSEPLIGRKK TDELPQLVTL PHPNLHGPEI
     LDVPSTVQKT PFITNPGYDT ENGIQLPGTT HQQPSVGQQM IFEEHGFRRT TPPTAATPVR
     LRPRPYLPNV DEEVQIGHVP RGDVDYHLYP HVPGLNPNAS TGQEALSQTT ISWTPFQESS
     EYIISCQPVG TDEEPLQFQV PGTSTSATLT GLTRGVTYNI IVEALQNQRR HKVREEVVTV
     GNAVSEGLNQ PTDDSCFDPY TVSHYAIGEE WERLSDAGFK LTCQCLGFGS GHFRCDSSKW
     CHDNGVNYKI GEKWDRQGEN GQRMSCTCLG NGKGEFKCDP HEATCYDDGK TYHVGEQWQK
     EYLGAICSCT CFGGQRGWRC DNCRRPGAAE PSPDGTTGHT YNQYTQRYNQ RTNTNVNCPI
     ECFMPLDVQA DRDDSRE
//
